Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia

The PI3K/Akt pathway—and in particular PI3Kδ—is known for its role in drug resistant B-cell acute lymphoblastic leukemia (B-ALL) and it is often upregulated in refractory or relapsed B-ALL. Myc proteins are transcription factors responsible for transcribing pro-proliferative genes and c-Myc is often...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Yongsheng, Kim, Hye Na, Ogana, Heather A., Wan, Zesheng, Hurwitz, Samantha, Nichols, Cydney, Abdel-Azim, Nour, Coba, Ariana, Seo, Seyoung, Loh, Yong-Hwee Eddie, Gang, Eun Ji, Abdel-Azim, Hisham, Hsieh, Chih-Lin, Lieber, Michael R., Parekh, Chintan, Pal, Dhananjaya, Bhojwani, Deepa, Durden, Donald L., Kim, Yong-Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671162/
https://www.ncbi.nlm.nih.gov/pubmed/34926269
http://dx.doi.org/10.3389/fonc.2021.766888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671162/
https://www.ncbi.nlm.nih.gov/pubmed/34926269
http://dx.doi.org/10.3389/fonc.2021.766888

Ejemplares similares